Safety of histamine-2 receptor blockers in hospitalized VLBW infants

Early Human Development

Volumn 99, Issue , 2016, Pages 27-30

  Romaine, Andrew ^a   Ye, Daniel ^a   Ao, Zachary ^a   Fang, Francia ^a   Johnson, Octavious ^a   Blake, Taylor ^a   Benjamin, Daniel K ^a   Cotten, C Michael ^a   Testoni, Daniela ^a   Clark, Reese H ^b   Chu, Vivian H ^a   Smith, P Brian ^a   Hornik, Christoph P ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b Pediatrix Obstetrix Center for Research and Education   (United States)

Author keywords

H2 blockers; Histamine 2 receptor antagonists; Infants; Necrotizing enterocolitis

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST;

ARTICLE; CHILD DEATH; DRUG FATALITY; DRUG SAFETY; DRUG USE; ELECTRONIC HEALTH RECORD; FEMALE; GESTATIONAL AGE; HIGH RISK POPULATION; HOSPITALIZED INFANT; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NECROTIZING ENTEROCOLITIS; NEWBORN INTENSIVE CARE; RISK ASSESSMENT; SEPSIS; TREND STUDY; UNITED STATES; VERY LOW BIRTH WEIGHT; CLINICAL TRIAL; INFANT MORTALITY; MULTICENTER STUDY; NEONATAL INTENSIVE CARE UNIT; NEWBORN; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA;

ENTEROCOLITIS, NECROTIZING; FEMALE; HISTAMINE H2 ANTAGONISTS; HUMANS; INFANT; INFANT MORTALITY; INFANT, NEWBORN; INFANT, VERY LOW BIRTH WEIGHT; INTENSIVE CARE UNITS, NEONATAL; MALE; RETROSPECTIVE STUDIES; SEPSIS;

EID: 84978149825     PISSN: 03783782     EISSN: 18726232     Source Type: Journal    
DOI: 10.1016/j.earlhumdev.2016.05.010     Document Type: Article

References (23)

1. [1] van der Pol, R., Langendam, M., Benninga, M., van Wijk, M., Tabbers, M., Efficacy and safety of histamine-2 receptor antagonists. JAMA Pediatr. 168:10 (Oct 2014), 947–954.
2. [2] Malcolm, W.F., Cotten, C.M., Metoclopramide, H2 blockers, and proton pump inhibitors: pharmacotherapy for gastroesophageal reflux in neonates. Clin. Perinatol. 39:1 (Mar 2012), 99–109.
3. [3] Orenstein, S.R., Blumer, J.L., Faessel, H.M., McGuire, J.A., Fung, K., Li, B.U., et al. Ranitidine, 75 mg, over-the-counter dose: pharmacokinetic and pharmacodynamic effects in children with symptoms of gastro-oesophageal reflux. Aliment. Pharmacol. Ther. 16:5 (May 2002), 899–907.
4. [4] Cucchiara, S., Staiano, A., Romaniello, G., Capobianco, S., Auricchio, S., Antacids and cimetidine treatment for gastro-oesophageal reflux and peptic oesophagitis. Arch. Dis. Child. 59:9 (Sep 1984), 842–847.
5. [5] Oderda, G., Dell'Olio, D., Forni, M., Farina, L., Tavassoli, K., Ansaldi, N., Treatment of childhood peptic oesophagitis with famotidine or alginate-antacid. Ital. J. Gastroenterol. 22:6 (Dec 1990), 346–349.
6. [6] Cucchiara, S., Minella, R., Iervolino, C., Franco, M.T., Campanozzi, A., Franceschi, M., et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Arch. Dis. Child. 69:6 (Dec 1993), 655–659.
7. [7] Ummarino, D., Miele, E., Masi, P., Tramontano, A., Staiano, A., Vandenplas, Y., Impact of antisecretory treatment on respiratory symptoms of gastroesophageal reflux disease in children. Dis. Esophagus 25:8 (2012), 671–677.
8. [8] Cucchiara, S., Gobio-Casali, L., Balli, F., Magazzu, G., Staiano, A., Astolfi, R., et al. Cimetidine treatment of reflux esophagitis in children: an Italian multicentric study. J. Pediatr. Gastroenterol. Nutr. 8:2 (Feb 1989), 150–156.
9. [9] Orenstein, S.R., Shalaby, T.M., Devandry, S.N., Liacouras, C.A., Czinn, S.J., Dice, J.E., et al. Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. Aliment. Pharmacol. Ther. 17:9 (2003), 1097–1107.
10. [10] Simeone, D., Caria, M.C., Miele, E., Staiano, A., Treatment of childhood peptic esophagitis: a double-blind placebo-controlled trial of nizatidine. J. Pediatr. Gastroenterol. Nutr. 25:1 (Jul 1997), 51–55.
11. [11] Guillet, R., Stoll, B.J., Cotten, C.M., Gantz, M., McDonald, S., Poole, W.K., et al. Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics 117:2 (Feb 2006), e137–e142.
12. [12] Bilali, A., Galanis, P., Bartsocas, C., Sparos, L., Velonakis, E., H2-blocker therapy and incidence of necrotizing enterocolitis in preterm infants: a case-control study. Pediatr. Neonatol. 54:2 (Apr 2013), 141–142.
13. [13] Terrin, G., Passariello, A., De Curtis, M., Manguso, F., Salvia, G., Lega, L., et al. Ranitidine is associated with infections, necrotizing enterocolitis, and fatal outcome in newborns. Pediatrics 129:1 (Jan 2012), e40–e45.
14. [14] Malcolm, W.F., Gantz, M., Martin, R.J., Goldstein, R.F., Goldberg, R.N., Cotten, C.M., Use of medications for gastroesophageal reflux at discharge among extremely low birth weight infants. Pediatrics 121:1 (Jan 2008), 22–27.
15. [15] Spitzer, A.R., Ellsbury, D.L., Handler, D., Clark, R.H., The Pediatrix BabySteps Data Warehouse and the Pediatrix QualitySteps improvement project system–tools for “meaningful use” in continuous quality improvement. Clin. Perinatol. 37:1 (Mar 2010), 49–70.
16. [16] Olsen, I.E., Groveman, S.A., Lawson, M.L., Clark, R.H., Zemel, B.S., New intrauterine growth curves based on United States data. Pediatrics 125:2 (Feb 2010), e214–e224.
17. [17] Gupta, R.W., Tran, L., Norori, J., Ferris, M.J., Eren, A.M., Taylor, C.M., et al. Histamine-2 receptor blockers alter the fecal microbiota in premature infants. J. Pediatr. Gastroenterol. Nutr. 56:4 (Apr 2013), 397–400.
18. [18] Ellsbury, D.L., Ursprung, R., A quality improvement approach to optimizing medication use in the neonatal intensive care unit. Clin. Perinatol. 39:1 (Mar 2012), 1–10.
19. [19] Ericson, J.E., Arnold, C., Cheeseman, J., Cho, J., Kaneko, S., Wilson, E., et al. Use and safety of erythromycin and metoclopramide in hospitalized infants. J. Pediatr. Gastroenterol. Nutr. 61:3 (Sep 2015), 334–339.
20. [20] Mahon, B.E., Rosenman, M.B., Kleiman, M.B., Maternal and infant use of erythromycin and other macrolide antibiotics as risk factors for infantile hypertrophic pyloric stenosis. J. Pediatr. 139:3 (Sep 2001), 380–384.
21. [21] Tolia, V., Calhoun, J., Kuhns, L., Kauffman, R.E., Randomized, prospective double-blind trial of metoclopramide and placebo for gastroesophageal reflux in infants. J. Pediatr. 115:1 (Jul 1989), 141–145.
22. [22] EryPed (erythromycin ethylsuccinate for oral suspension) [package insert]. Atlanta, GA: Arbor Pharmaceuticals.
23. [23] Reglan (metoclopramide hydrochloride) injection, solution. 2010, Baxter Healthcare Corporation, Deerfield, IL.